Investors Seek Improved Weight-Loss Drugs: Companies Forge Ahead In Developing Nausea-Free Alternatives To Wegovy
Portfolio Pulse from Vandana Singh
Novo Nordisk's weight-loss drug Wegovy has been successful but has side effects like severe nausea, leading to discontinuation by many users. This has sparked interest from investors and biotech companies to develop alternative weight-loss drugs with fewer side effects. Companies like Rivus Pharmaceuticals, Glyscend Therapeutics, and Antag Therapeutics are developing such alternatives. Major pharmaceutical companies like Novo Nordisk and Eli Lilly are also working on second-generation weight-loss drugs.
July 07, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly is working on developing second-generation weight-loss drugs.
Eli Lilly is working on developing second-generation weight-loss drugs. This could potentially open up a new revenue stream for the company if the drugs are successful and approved for use.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70
NEUTRAL IMPACT
Novo Nordisk's weight-loss drug Wegovy has side effects leading to discontinuation by many users. The company is working on developing second-generation weight-loss drugs.
Novo Nordisk's Wegovy has been successful but its side effects have led to discontinuation by many users. This could potentially impact the company's revenues from the drug. However, the company is also working on developing second-generation weight-loss drugs which could offset any potential losses.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90